Inoxell strikes patent deal with US biotech company  

Rigel Pharmaceuticals Inc. and Inoxell A/S enter global patent settlement

US biotech company Rigel Pharmaceuticals, Inc. and Zealand-based Inoxell A/S have announced that the two companies have entered a global patent settlement concerning drug target identification technologies.  The agreement,  involving cross-licensing and joint ownership of certain patents, allows for worldwide freedom of operation for both companies.  Rigel has awarded Inoxell a non-exclusive license to a number of additional patents relevant for the drug target identification process. The financial terms of the settlement  were not disclosed.


Drug discovery company Inoxell A/S was formed as a spinout from Pharmexa (formerly M & E Biotech) in 2001. The company identifies novel targets for drug action in order to discover and develop new and better pharmaceuticals. Inoxell currently has a collaboration with Astra Zeneca. With its patented CellScreen technology the company has a unique way of identifying and validating drug targets.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×